The the 9th Annual Liquid Biopsy for Precision Oncology Summit focuses on advancing liquid biopsy technologies, refining biomarker discovery, and optimizing their clinical and commercial applications to enhance precision oncology and patient outcomes.
Topics
- Transforming Molecular Insights into Actionable Tools to Enable Real Time Monitoring of Patients & Drive Precision Oncology
- Defining Robust Clinical Endpoints with MRD to Enhance Long-Term Survival Prediction & Optimize Patient Outcomes
- Track A: Discovery & Technology Innovation
- Enhancing Predictive Biomarkers through Multi-Omics & Advanced MRD Detection for Refined Patient Selection Strategies
- Track B: Clinical Development & Commercialization
- Leveraging Liquid Biopsies to Optimize Clinical Trial Design for Better Dosage Regimes & Enhanced Patient Selection
- Innovating Liquid Biopsy Strategies to Decode Tumor Complexity & Enhance Oncology Insights for Better Cancer Treatments
- Streamlining Liquid Biopsy Operations & Advancing Biomarker Analysis to Promote Routine Use of Liquid Biopsies in Clinical Settings
- Navigating Complex Regulatory Landscapes to Overcome Global Barriers & Achieve Ubiquitous Approvals
- Track A: Discovery & Technology Innovation
- Harnessing Multi-Analytes to Advance Comprehensive Oncology Understanding to Unlock Deeper Insights into Patient Surveillance
- Overcoming Reimbursement Barriers to Enhance Patient Access to Innovative Therapies
- Optimizing Biomarker Discovery with Unparalleled Liquid Biopsy Analysis to Enhance Therapeutic Efficacy in Clinical Trials
- Accelerating Liquid Biopsy Adoption through Optimal Implementation & Commercialization to Maximize Clinical Impact & Patient Access
- Enhancing Liquid Biopsy Utilization through Strengthened Compliance & Strategic Partnerships for Global Market Succes
